Navigation Links
Sinapis Pharma Closes Series 'A' Financing
Date:11/17/2009

JACKSONVILLE, Fla., Nov. 17 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.

The current financing will allow the company to reach significant development milestones. Investigational New Drug (IND) application submission to the FDA is anticipated for December 2009 with a Phase I clinical trial commencing in the first quarter of 2010. A Phase II proof of concept study is expected to commence in late 2010 for the stroke indication in humans.

Dr. Donald Picker, Sinapis CEO, relates: "We are excited that we can begin the development of methamphetamine for stroke. We have a rapid, inexpensive development pathway to proof of principle in man within 24 months due to the drug's previous human use for other indications, and anticipate being the first drug to enter stroke clinical trials with solid 6-12 hour pre-clinical data."

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.

For more information contact Dr. Picker at Don.Picker@gmail.com.

SOURCE Sinapis Pharma, Inc.


'/>"/>
SOURCE Sinapis Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
(Date:5/2/2017)... -- George Clinical, a leading full-service CRO in the ... a Memphis -based leader in ... George Clinical has acquired Vector Oncology,s Pharma Services (CRO) Division. ... of strengthening the ability of George Clinical to ... the Asia-Pacific , the world,s ...
(Date:5/2/2017)... ROBLES, Calif. , May 2, 2017  Bayer and ... received grants from Healthy Hives 2020, a $1 million research ... the U.S. by the end of 2020. ... Olav Rueppell , University of North Carolina at Greensboro, ... available honey bees; Dr. Edmund Stark ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... and interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance ... scalable and secure cloud platform for medical image management. At the core is ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Manju ... comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the ... she offers convenient, clear braces in Cincinnati, OH. Patients no longer need to feel ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New ... for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. ... of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate ... in his field by attending numerous CE courses each year. His recent course, ...
(Date:5/24/2017)... ... ... Medic CE , a Career Step company, is sponsoring a live, ... the Journal of Emergency Medical Services (JEMS). The free webinar, to be held on ... Rommie Duckworth, LP, a career fire captain as well as founder and director of ...
Breaking Medicine News(10 mins):